Ernexa Therapeutics (ERNAW) Share-based Compensation (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Share-based Compensation of $309000.0 for Q1 2026, down 38.45% on a YoY basis from $502000.0 in Q1 2025, and up 130.23% quarter-over-quarter from -$1.0 million in Q4 2025.
Ernexa Therapeutics (ERNAW) Share-based Compensation (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $309000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 38.45% year-over-year to $309000.0; the trailing twelve-month figure through Mar 2026 stood at -$52000.0 (down 102.99% YoY), and the FY2025 full-year result was $141000.0, down 90.72% from the prior year.
- Share-based Compensation for Q1 2026 stood at $309000.0, up from -$1.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $1.2 million in Q1 2022, with the low at -$1.0 million in Q4 2025.
- Historically, Share-based Compensation has averaged $361588.2 across 5 years, with a median of $397000.0 in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 182.34% — and 2025, when it sank 349.27%.
- Ernexa Therapeutics' Share-based Compensation stood at $397000.0 in 2022, then plunged by 58.44% to $165000.0 in 2023, then soared by 148.48% to $410000.0 in 2024, then tumbled by 349.27% to -$1.0 million in 2025, then jumped by 130.23% to $309000.0 in 2026.
- The last three Share-based Compensation figures came in at $309000.0 (Q1 2026), -$1.0 million (Q4 2025), and $293000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Ernexa Therapeutics | - | - | - | 309,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 309,000.00 |
| Mar 31, 2026 | 309,000.00 |
| Dec 31, 2025 | -1.02 Mn |
| Dec 31, 2025 | -1.02 Mn |
| Sep 30, 2025 | 293,000.00 |
| Sep 30, 2025 | 293,000.00 |
| Jun 30, 2025 | 368,000.00 |
| Jun 30, 2025 | 368,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 410,000.00 |
| Dec 31, 2024 | 410,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 423,000.00 |
| Jun 30, 2024 | 423,000.00 |
| Mar 31, 2024 | 282,000.00 |
| Mar 31, 2024 | 282,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |